Biliary pseudolithiasis has been reported in patients who received ceftriaxone therapy. To examine this phenomenon further, serial gallbladder sonograms were evaluated in 44 adult patients who received intravenous ceftriaxone at 2 g or a placebo daily for 14 days in a double-blind controlled study. Ultrasound examinations of gallbladders were performed on days 1 and 14 of therapy and 2 weeks posttherapy if abnormalities were observed on day 14. Eight patients were unevaluable because of abnormal base-line gallbladder sonograms. Thirty-six patients (ceftriaxone, n = 28; placebo, n = 8) demonstrated normal baseline gallbladder sonograms and were evaluated for the development of change. A total of 6 of 28 (21.4%) ceftriaxone-treated patients and 1 of 8 (12.5%) patients who received the placebo demonstrated abnormal gallbladder sonograms on day 14 (P = 0.491). Four of the six ceftriaxone-treated patients demonstrating abnormal sonograms were clinically asymptomatic, while two patients reported vomiting. The abnormal sonograms of gallbladders of patients treated with ceftriaxone returned to normal between 9 and 26 days posttherapy. These data suggest an association between ceftriaxone treatment and the development of gallbladder abnormalities on ultrasound examination which resolve spontaneously on discontinuation of ceftriaxone therapy.
The term pseudolithiasis has been used previously (K. Heim-Duthoy, E. Caperton, G. Matzke, and P. Peterson, Program Abstr. 28th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 556, 1988) to report the preliminary findings of the study reported here. Pseudolithiasis was used to describe sonographic abnormalities in the gallbladders of patients treated with ceftriaxone in an attempt to differentiate the reversible abnormalities which have been observed in ceftriaxone-treated patients from those of true operative stones.
Biliary pseudolithiasis has been reported in patients, including children, who have received high-dose intravenous bolus ceftriaxone therapy (3) (4) (5) patients; a 5-MHz transducer was used in thinner patients. Patients were routinely studied in both the supine and left posterior oblique positions and, if necessary, in an upright, sitting position. Longitudinal and transverse images of the right upper quadrant were obtained, with emphasis on the gallbladder and biliary tree. Gallstones were diagnosed by demonstrating intraluminal echoes which had acoustical shadowing and were usually mobile with patient repositioning. Echogenic bile without acoustical shadowing was considered sludge. All results were interpreted by the same investigator, who was blinded to treatment randomization and treatment order.
Clinical evaluations, i.e., medical history, physical examination, and laboratory evaluation, were performed pretherapy, during therapy (day 7), posttherapy, and at the time of follow-up if symptomatology or sonographic changes were detected.
Significant differences in demographic characteristics between groups were assessed by an independent t test. Sex distribution differences between groups were assessed by a chi-square analysis. The incidence of gallbladder abnormality developments in patients who received placebo or ceftriaxone were evaluated by a chi-square analysis. Statistical significance was assessed at a level of P < 0.05. RESULTS A total of 44 patients were randomized to received either ceftriaxone or placebo and underwent initial gallbladder ultrasonography. Eight patients (two who received placebo and six who received ceftriaxone) were unevaluable because of abnormal gallbladder sonograms on day 1. The demographic characteristics of the 36 evaluable patients in the corresponding treatment groups are presented in Table 1 .
Abnormal gallbladder sonograms were demonstrated on day 14 in 1 of 8 (12.5%) and 6 of 28 (21.4%) evaluable patients treated with placebo and ceftriaxone, respectively. The difference between the two groups was not statistically significant (P = 0. Eight patients treated with ceftriaxone and with gallbladder sonograms interpreted as gallstones are known to have undergone cholecystectomy (unpublished data on file, Hoffmann-La Roche, Inc., 1989). One of these patients, an 85-year-old female, had true gallstones. Gallbladders of the remaining seven patients contained sandlike, semisolid particles and were reported as "not gallstones."
In this prospective randomized, double-blind, placebocontrolled trial, 21.4% (6 of 28) of adult patients who received ceftriaxone developed abnormalities on gallbladder ultrasound examination. In contrast, one of eight patients who received placebo developed abnormalities on ultrasound examination. Although the differences in the incidence of abnormal gallbladder sonograms in patients who received ceftriaxone and placebo were not statistically significant (P = 0.491), abnormalities were observed on ultrasound examination. The gallbladder abnormalities observed on ultrasound examination were interpreted as gallstones in five patients and as sludge in two patients ( Table 3) .
The findings in the eight unevaluable patients with abnormal sonograms at base line add to the complexity of this phenomenon. The two unevaluable patients who initially received placebo continued to have positive sonographic readings following placebo administration and were subsequently crossed over to receive ceftriaxone; after a full course of ceftriaxone, the sonogram in one patient was unchanged, while in the other the sonogram was interpreted as cleared. The remaining patients who were unevaluable received ceftriaxone initially, and no change was demon- (1) observed a threefold interindividual variation in the biliary excretion of ceftriaxone. Furthermore, ceftriaxone biliary excretion has been correlated with the rate of bile acid secretion. If the mechanism of ceftriaxone-induced pseudolithiasis in humans is precipitation of the antibiotic in the gallbladder, individuals with increased bile acid secretion may be predisposed to the development of this adverse effect.
Because of its excellent antimicrobial spectrum of activity and attractive pharmacokinetic characteristics, ceftriaxone is used commonly in patients with serious bacterial infections. Apparent biliary pseudolithiasis may occur in patients who receive ceftriaxone. In our study, abnormal gallbladder sonograms in patients who received ceftriaxone were observed as echos with shadows (five of six patients) and were interpreted as gallstones. Furthermore, these abnormalities resolved spontaneously.
Awareness that sonographic interpretations of gallstone disease in patients who receive ceftriaxone may actually represent apparent biliary pseudolithiasis, a spontaneously reversible abnormality, will be conducive toward a conservative expectant approach to treatment with avoidance of surgery.
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